Deferred Tax Assets, Valuation Allowance of Oric Pharmaceuticals, Inc. from 31 Dec 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Oric Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2025.
  • Oric Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $212,603,000, a 23% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Oric Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $212,603,000 +$40,041,000 +23% 31 Dec 2025 10-K 23 Feb 2026 2025 FY
Q4 2024 $172,562,000 +$39,597,000 +30% 31 Dec 2024 10-K 23 Feb 2026 2025 FY
Q4 2023 $132,965,000 +$31,520,000 +31% 31 Dec 2023 10-K 18 Feb 2025 2024 FY
Q4 2022 $101,445,000 +$26,629,000 +36% 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q4 2021 $74,816,000 +$25,309,000 +51% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q4 2020 $49,507,000 +$20,924,000 +73% 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q4 2019 $28,583,000 +$8,673,000 +44% 31 Dec 2019 10-K 23 Mar 2021 2020 FY
Q4 2018 $19,910,000 31 Dec 2018 10-K 23 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.